医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in US for the Treatment of Severe Dry Eye

2013年05月20日 PM03:55
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno, Ltd. (JASDAQ:4573):

This is to announce start of the patient enrollment of the first stage of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101(Note 1); hereafter RU-101 ophthalmic solution), which is being developed in our company, in US for the treatment of severe dry eye.

We are currently developing RU-101 ophthalmic solution to treat severe dry eye for which no effective treatment has been established.

The trials consist of two stages. At the first stage, the safety will be mainly assessed using placebo (without the active ingredient) as control to evaluate maximum dosage of RU-101 ophthalmic solution for treatment of patients with severe dry eye. At the next stage, RU-101 ophthalmic solution of maximum dosage safety of which will have been confirmed at the first stage will be instilled for 12 weeks, and the safety and effectiveness will be evaluated using placebo as control.

The trial will be performed as a double masking test(Note 2) at each stage. Maximum 120 study subjects will be totally involved in the first and second stage studies in 10 US medical facilities.

Yukihiko Mashima MD, PhD, an ophthalmologist and the president of R-Tech Ueno, said ‘I am very pleased that initial cases have been enrolled in a Phase I/II clinical study of RU-101 ophthalmic solution in US. The enrollment launched immediately after the approval of our IND(Note 3) application by FDA(Note 4), reflecting the high medical needs, I think. Dry eye is a modern disease which reportedly one of three office workers suffers. Our target, market for dry eye, is estimated to be 1,500 million USD, which is still increasing. We will promote the development of the drug for moderate to severe dry eye, an unmet medical need where no sufficient treatment method has been established.

We attempt to rapidly complete the case enrollment with cooperation of people such as ophthalmologists and patients and promote the first stage study. Also, we will start the second stage as soon as possible and aim rapid approval of this solution for patients with dry eye who need the solution.

(Note 1) About RU-101

RU-101 is a project that is aimed at the development of ophthalmic solutions for the treatment of corneal epithelial diseases including dry eye, focusing on serum component albumin. Dry eye is a chronic and multifactor ophthalmic disease characterized by disorders of the lacrimal layer and the eye surface. R-Tech Ueno has confirmed that serum albumin enhances the production of mucin, one of the components of tears, in an experiment in conjunctival epithelial cells, and also has intellectual property rights concerning the treatment of dry eye with albumin.

(Note 2) Double masking test

To avoid the effect of a placebo (effect of an assumption), study is performed without informing both medical doctors and patients (subjects) of which is effective ‘solution’ and non-effective ‘placebo’. The term means that all those involved such as subjects, medical doctors, clients, and other staffs who work on the treatment and clinical assessment in the facility do not know which solutions, true drug or placebo, are administered to the subjects.

(Note 3) About IND (Investigational New Drug)

To perform clinical trial in United States, it is necessary to submit an information package which includes active pharmaceutical ingredients, drug formulation, non-clinical study, and design of the clinical study regarding the novel candidate drug to FDA, and obtain the approval to perform the clinical trial. The candidate drug itself and/or submitted information package are called IND (Investigational New Drug).

(Note 4) About FDA (Food and Drug Administration)

A US governmental organization in charge of marketing approval of food, drugs, cosmetics, medical device, etc. and control of illegal products, etc.

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors.” We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402